Articles from Rondo Therapeutics

Rondo Therapeutics, a clinical-stage biopharmaceutical company pioneering next-generation T-cell engaging bispecific antibodies for solid tumors, today announced that the first patient has been dosed in its Phase 1/1b clinical trial evaluating RNDO-564, a first-in-class bispecific antibody targeting CD28 and Nectin-4, in adults with relapsed or refractory locally advanced or metastatic urothelial carcinoma (mUC) and other solid tumors associated with Nectin-4 expression.

Rondo Therapeutics, a privately held biopharmaceutical company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced the publication detailing the discovery and preclinical development of RNDO-564, a CD28 x Nectin-4 bispecific antibody in the Journal for ImmunoTherapy of Cancer (JITC).

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced that data from preclinical studies of RNDO-564, a novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer, is being presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 13-15, 2025, in San Francisco, CA.

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced a research collaboration and license agreement with Eli Lilly and Company. This collaboration will combine Rondo Therapeutics’ proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies for solid tumor treatment.

Rondo Therapeutics, a private biopharmaceutical company pioneering next-generation bispecific antibody platforms, has named Thomas Manley, M.D., as Chief Medical Officer (CMO). Dr. Manley will lead the clinical development of Rondo's innovative T-cell engaging immunotherapies designed to treat solid tumors, including metastatic bladder and ovarian cancers. With more than 25 years in oncology research and development, Dr. Manley brings expertise from both leading biotech and major pharmaceutical companies.

Rondo Therapeutics, a privately-held biopharmaceutical company advancing next-generation immuno-oncology platforms, announces the appointment of Steven James to its Board of Directors. Mr. James brings over three decades of biopharmaceutical experience to Rondo’s Board of Directors. He was instrumental in building and leading several companies into the clinic, resulting in $2B+ in M&A value for stakeholders. Mr. James’ addition to the Board of Directors strengthens Rondo’s leadership team as the company continues to drive development of T-cell engaging bispecific antibodies for solid tumors.

Rondo Therapeutics, a biopharmaceutical company pioneering next-generation bispecific antibodies, announces oral presentations at both Protein & Antibody Engineering Summit (PEGS) and Antibody Engineering & Therapeutics (AET) EU.